CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:

COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON



October 23, 2006

Attorney Docket No. B45187C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Cohen, et al.

October 23, 2006

Serial No.:

10/789,758

Group Art Unit No.: 1645

Filed:

February 27, 2004

Examiner: N. Minnifield

For:

VACCINES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Information Disclosure Statement Under 37 C.F.R. §1.97(c)

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed under the provisions of 37 C.F.R. §1.97(c), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

10/26/2006 WASFAW1 00000018 192570 10789758

03 FC:1806

180.00 DA

Serial No.: 10/789,758 Group Art Unit No.: 1645

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,

Andrea V. Lockenour Attorney for Applicants Registration No. 51,962

GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Phone (610) 270-7568 Facsimile (610) 270-5090

						·			sheet 1 c	<u> </u>
	Form PTO	-1449		epartment of Comrent and Trademark		B45187C1	•	SERIAL NO. 10/789,758	;	
	INFO	RMA	TION DISCLOSU	RE STATEMEN	T	APPLICANT	-			
1	PE		BY APPLICAL	TI		Cohen, et al.				
	40) "	an anyonal abouts if r	200000011		FILING DATE		GROUP		
1	2 5 2006	ų) (U	se several sheets if n	ecessary)		February 27, 2004		1043		
	, d			U.S. P	ATEN	T DOCUMENTS				
1	Document Number Date				Name	Class	Subclass	Filing Date If Appropriate		
-	miliai								н Арри	орпате
Į										
					I PAT	ENT DOCUMENTS			T	l-tion
			Document Number	Date		Country	Class	Subclass	Trans Yes	No
ı		BA	EP0278940A2	25 Jan. 1988	Euro	pe				
Ì		-								
L			OTHER D	OCUMENTS //sa	li idin n	Author, Title, Date, Pertin	ont Pages	Eta l	L	
ſ						of the RTS,S/AS02 p			m Mala	ria
		CA				Trop. Med Hyg. (2003				
Ĭ		СВ	Ambroise-Thoma	as P., "Vaccinati	on ag	ainst malaria. Disapp	oinments	and hopes,	" Bullet	in de
ļ						v. 1997) 181(8):167-4		71		
		CC				02 malaria vaccine ag				
١			2001) 358:1927-		nen 11	The Gambia: a radomised trial," The Lancet (Dec. 8,				
ł		CD			ccine	"," Current Opinion in	ı Anti-inf	ective Inves	tigation	al
			Drugs (2000) 2(1):83-8 <u>7</u> .						\
		CE				es: From the Laborat			rrent D	rug
-		CE	· · ·			olic Disorders (2002)		<i>1</i> .		
ļ		CF			`	2005)365:1487-1498.		•	• ,	
		CG				ased, multi-stage, mu alter Reed Army Insti				
			(2005)23:2243-2		ic wa	inci Recu Ailily ilisu	iule of Ke	scarcii, va	iccine	
ŀ		СН			Glaxo	SmithKline Biologic	als,) "Ad	juvanted R7	S,S and	d
			Other Protein-Ba	sed Pre-Erythro	cytic	Stage Malaria Vaccin	es," New	Generation	Vaccin	ies 3 rd
			Edition(2004):85		 	 		1	, ,	
l		CI	Pinder M. et al.,	"Cellular immur	nity in	duced by the Recoml i-immune adults in T	oinant <i>Pla</i>	ismodium fo io "Clin Exr	ilcipari Mmni	ım nol
			(2004) 135:286-2		ii seiii	1-minune addits m 1	ne Gamo	іа, Сіт.Ехр	. Immu	noi.
ŀ	<u> </u>	CJ			cy an	d Immune Responses	followin	g Immunica	tion wi	th the
			RTS, S Malaria V	Jaccine," The Jo	ourna	l of Infectious Disease	es (Oct 19	998) 178(4):	1139-1	
		CK	Sun, et al., "Proto	ective Immunity	Indu	ced with Malaria Vac	cine, RTS	S,S, is Linke	ed to	
l						oite Protein-Specific		CD°T Cells	s Produ	cing
ŀ		CL				2003) 171:6961-6967 uvant MPL, Enhances		v Profiles i		
						as the Potential to Im				y
						(2)135-139 (2001), ab				-
ſ	EXAMINE	₹				DATE CONSIDERED				
		_								.,
	·EXAMINE in conformation	R: Initi ance a	al if citation considere nd not considered. Inc	d, whether or not cit clude copvof this for	tation i m with	s in conformance with MP next communication to a	EP 609; Dr oplicant.	aw line throug	n citation	if not
L										

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10789758
	Filing Date		2004-02-27
INFORMATION DISCLOSURE	First Named Inventor	Joseph	n Cohen
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1645
(Not for Submission under 37 Of K 1.33)	Examiner Name	Nita M	Minnifield
	Attorney Docket Numb	er	B45187 C1

					U.S.F	ATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	Name of Pate of cited Docur	ntee or Applicant ment	Releva		Lines where ges or Releva	
	1				_						
If you wisl	h to ac	ld additional U.S. Pater	nt citatio	n informa	ation ple	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	ATION PUBL	ICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Releva	,Columns, ant Passaç s Appear	Lines where ges or Relev	ant
	1	· '									
If you wis	h to a	l dd additional U.S. Publi	shed Ap			n information p		d buttor	Add Remove		
Examiner	Cite No	Foreign Document Number ³	Countr Code ²	y	Kind Code ⁴	Publication	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	Т5
NMM	1	W002/38176	WO		A2	2002-05-16	GSK Biologicals				
NMM	2	WO2004/037189	wo		A2	2004-06-04	GSK Biologicals				
NMM	3	WO2006/029887	wo		A2	2006-03-23	GSK Biologicals				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10789758	
Filing Date		2004-02-27	
First Named Inventor	Jose	ph Cohen	
Art Unit		1645	
Examiner Name	Nita	M Minnifield	
Attorney Docket Numb	er	B45187 C1	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

If you wis	h to ac	dd additional Foreign Patent Document citation information plea	ase click the Add button						
		NON-PATENT LITERATURE DOC	UMENTS	Remove					
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the (book, magazine, journal, serial, symposium, catalog, etc), da publisher, city and/or country where published.	e article (when appropri ite, pages(s), volume-iss	ate), title of the item sue number(s),	T 5				
NMM	1	Alonso, et al., "Efficacy of the RTS,S/AS02A vaccine against Plasme African children: randomized controlled trial." Lancet 364:1411-142	odium falciparum infection 20 (2004).	and disease in young					
NMM	2	Nussenweig, RS and Zavala, F., "A Malaria Vaccine Based on Spor 336:128-130 (1997)	ozoite Antigen" New Engl	and Journal of Medicine					
NMM	3	Van Der Perre, P and Berret, J. "Vaccine efficacy: winning the battl 364:1380-1383 (2004)	e (not war) against malaria	ı." Lancet					
If you wis	h to ac	dd additional non-patent literature document citation informatio	n please click the Add b	utton Add					
-		EXAMINER SIGNATURE							
Examiner	Signa	ature /N. M. Minnifield/ (06/12/2006)	Date Considered	06/12/2006					
*EXAMIN citation if	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
Standard S	T.3). ³ F cument	of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter of For Japanese patent documents, the indication of the year of the reign of the Et by the appropriate symbols as indicated on the document under WIPO Standaranslation is attached.	Emperor must precede the ser	ial number of the patent doc	ument.				

Notice of References Cited Application/Control No. 10/789,758 Examiner N. M. Minnifield Applicant(s)/Patent Under Reexamination COHEN ET AL. Page 1 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2006/0073171	04-2006	Cohen, Joseph	424/272.1
*	В	US-2006/0051372	03-2006	Vande Velde, Vincent	424/202.1
*	С	US-2005/0197308	09-2005	Dalton et al.	514/044
*	D	US-6,942,866	09-2005	Birkett, Ashley J.	424/268.1
	E	US-			
	F	US-			
	G	US-			
	Н	US-			
	ı	US-			
	J	US-			
	К	US-			
	L	US-			
	М	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	EP 278940 A2	08-1988	EP	Cabezon et al	C12N 15/00
	0		<u> </u>			
	Р		<u></u>			
	Q					
	R					
	s					
	Т					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	υ	Ambrose, Bulletin de l'Academie nationale de medicine, Nov. 1997, 181/8:1637-1648 abstract only
	٧	Genton et al, Current Drug TargetsImmune, Endocrine & Metabolic Disorders, 2002, 2:255-267
	w	Stoute et al, Journal of Infectious Diseases, October 1998, 178/4:1139-1144
	x	Bojang et al, Lancet, December 2001, 358:1927-1934

^{*}A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited Application/Control No. 10/789,758 Examiner N. M. Minnifield Applicant(s)/Patent Under Reexamination COHEN ET AL. Page 2 of 3

U.S. PATENT DOCUMENTS

					-
*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	Н	US-			
	-	US-			
	J	US-			
	к	US-			
	L	US-		·	
	М	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					-
	0					
	Р					
	Q					
	R					
	s					
	Т					

NON-PATENT DOCUMENTS

		NON-PAIENT DOCUMENTS
*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Greenwood et al, Lancet, April 2005, 3665:1487-1498
	V	Alloueche et al, Am. J. Trop. Med. Hyg., 2003, 68/1:97-101
	w	Pinder et al, Clin. Exp. Immunol., 2004:135:286-293
	×	Heppner et al, Vaccine, 2005, 23:2243-2250

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Application/Control No. Applicant(s)/Patent Under Reexamination 10/789,758 COHEN ET AL. Notice of References Cited Art Unit Examiner Page 3 of 3 N. M. Minnifield 1645 **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	В	US-			
	С	US-			
	D	US-			
	Ε	US-			
	F	US-			
	G	US-			
	Н	US-			
	1	US-			
	j	US-			
	К	US-			
	L	US-			
	М	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	s					
	Т					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)					
	U	Sun et al, J. Immunology, 2003, 171:6961-6967					
	V	Heppner et al, In: New Generation Vaccines, editor Levine et al, 2004, 3 rd Edition, pp. 851-59					
	w	Burchmore, current Opinino in Anti-Infectious Investigational Drugs, 2000, 2/1:83-87					
	×						

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.